Assessment of drug-drug interaction in an elderly human immunodeficiency virus population: Comparison of 3 expert databases.
HIV/AIDS
drug interaction
drug safety
elderly
pharmacovigilance
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
25
03
2020
revised:
08
07
2020
accepted:
13
07
2020
pubmed:
23
7
2020
medline:
27
7
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Polypharmacy increase the risk of drug-drug interactions (DDIs) in the elderly population living with human immunodeficiency virus (HIV). Several expert databases can be used to evaluate DDIs. The aim of the study was to describe actual DDIs between antiretroviral drugs and comedications in an elderly population and to compare grading of the DDIs in 3 databases. All treatments of HIV-infected subjects aged 65 years and older were collected in 6 French HIV centres. Summary of Product Characteristic (SPC), French DDI Thesaurus (THES), and Liverpool HIV DDI website (LIV) were used to define each DDI and specific grade. DDIs were classified in yellow flag interaction (undefined grade in SPC and THES or potential weak interaction in LIV), amber flag interaction (to be considered/precaution of use in SPC and THES and potential interaction in LIV) and red flag interaction (not recommended/contraindication in SPC and THES and do not administer/contraindication in LIV). Among 239 subjects included, 60 (25.1%) had at least 1 DDI for a total of 126 DDIs: 23/126 red flag DDIs were identified in 17 patients. All these 23 DDIs were identified in LIV. THES and SPC missed 6 and 1 red flag DDIs, respectively. Seven of 23 red flag DDIs were identified in the 3 databases concomitantly. Polypharmacy is frequent in this elderly HIV population leading to DDI in a quarter of the subjects. The discrepancies between databases can be explained by differences in analysis methods. A consensus between databases would be helpful for clinicians.
Substances chimiques
Anti-Retroviral Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1194-1202Informations de copyright
© 2020 The British Pharmacological Society.
Références
Nozza S, Malagoli A, Maia L, et al. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother. 2017;72(10):2879-2886.
Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120-1126.
Hentzien M, Dramé M, Allavena C, et al. Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era--role of chronic renal disease. J Nutr Health Aging. 2016;20(4):408-414.
Guaraldi G, Malagoli A, Calcagno A, et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65-74 years and more than 75 years. BMC Geriatr [Internet]. 2018;18(1):99. https://doi.org/10.1186/s12877-018-0789-0
Livio F, Marzolini C. Prescribing issues in older adults living with HIV: thinking beyond drug-drug interactions with antiretroviral drugs. Ther Adv Drug Saf. 2019;10. https://doi.org/10.1177/2042098619880122
Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62(3):447-453.
Morillo-Verdugo R, Blanco Ramos JR, Abdel-Kader Martín L, Álvarez de Sotomayor M. The challenge of aging and pharmacoterapeutic complexity in the HIV + patient. Farm Hosp Organo Expresion Cient Soc Espanola Farm Hosp. 2018;42(3):120-127.
Gueler A, Moser A, Calmy A, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS Lond Engl. 2017;31(3):427-436.
Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355.
Kong AM, Pozen A, Anastos K, Kelvin EA, Nash D. Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis. AIDS Patient Care STDS. 2019;33(3):93-103.
Allavena C, Hanf M, Rey D, et al. Antiretroviral exposure and comorbidities in an aging HIV-infected population: the challenge of geriatric patients. PLoS ONE. 2018;13(9):e0203895.
Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 1 sept 2011;66(9):2107-2111.
Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS. 2012;26:S39-S53.
Gimeno-Gracia M, Crusells-Canales MJ, Armesto-Gómez FJ, Compaired-Turlán V, Rabanaque-Hernández MJ. Polypharmacy in older adults with human immunodeficiency virus infection compared with the general population. Clin Interv Aging. 2016;11:1149-1157.
Nolan L, O'Malley K. Prescribing for the elderly. Part I: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc. 1988;36(2):142-149.
Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. Association of age with Polypharmacy and Risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013;47(11):1429-1439.
Nadis® Fedialis Medica, France. Copyright© 2017 Advanced Biological Laboratories S.A.
Alexander SP, Kelly E, Marrion N. The concise guide to PHARMACOLOGY 2015/16: overview: the concise guide to PHARMACOLOGY 2015/16: overview. Br J Pharmacol. et al., 2015;172(24):5729-5743.
Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, Patel N. Comparing the frequencies of contraindicated drug-drug interactions between differing antiretroviral regimens in HIV-infected patients. Ann Pharmacother. 2017;51(5):365-372.
Iniesta-Navalón C, Franco-Miguel JJ, Gascón-Cánovas JJ, Rentero-Redondo L. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach. HIV Med. 2015;16(5):273-279.
Bastida C, Grau A, Márquez M, et al. Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population. Farm Hosp Organo Expresion Cient Soc Espanola Farm Hosp. 1 sept 2017;41(5):618-624.
Molas E, Luque S, Retamero A, et al. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients identified through a multidisciplinary team. HIV Clin Trials. 2018;19(1):1-7.
Monteith S, Glenn T. A comparison of potential psychiatric drug interactions from six drug interaction database programs. Psychiatry Res. 2019;275:366-372.
Ramos GV, Guaraldo L, Japiassú AM, Bozza FA. Comparison of two databases to detect potential drug-drug interactions between prescriptions of HIV/AIDS patients in critical care. J Clin Pharm Ther. 2015;40(1):63-67.
Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol. 2015;71(2):131-142.
Back D. 21st international workshop on co-morbidities and adverse drug reactions in HIV. Antivir Ther. 2019;24(Suppl 1):A1-A112.
Burger DM, Smolders EJ, Schapiro J, Drenth JPH, Back DJ. A call for a consortium for optimal Management of Drug-Drug Interactions in patient care. Clin Pharmacol Ther. 2017;102(3):391-394.
Naves O, Deysson M, Buxeraud J. Le résumé des caractéristiques du produit au cours du temps. Wwwem-Premiumcomdatarevues05153700v55i553S0515370015005029 [Internet]. 4 févr 2016 [cité 30 sept 2019]; Disponible sur: https://www.em-premium.com/article/1029942?redirectTo=EM
López-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan Á, et al. Polypharmacy and drug-drug interactions in people living with human immunodeficiency virus in the region of Madrid, Spain: a population-based study. Clin Infect Dis. 2020;71(2):353-362. https://doi.org/10.1093/cid/ciz811
Ranzani A, Oreni L, Agrò M, et al. Burden of exposure to potential interactions between antiretroviral and non-antiretroviral medications in a population of HIV-positive patients aged 50 years or older. JAIDS J Acquir Immune Defic Syndr. 2018;78(2):193-201.